victoza Drug Patent Profile

When do Victoza patents expire, and what generic alternatives are available?

Victoza is a drug marketed by Novo Nordisk Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-three patent family members in twenty-seven countries.

The generic ingredient in VICTOZA is liraglutide. There are seven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the liraglutide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Victoza

A generic version of victoza was approved as liraglutide by HIKMA on December 23^rd, 2024.

Summary for victoza

International Patents:	63
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	126
Patent Applications:	3,456
Drug Prices:	Drug price information for victoza
Drug Sales Revenues:	Drug sales revenues for victoza
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for victoza
What excipients (inactive ingredients) are in victoza?	victoza excipients list
DailyMed Link:	victoza at DailyMed

See drug prices for victoza

See drug sales revenues for victoza

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for victoza

Constraining patent/regulatory exclusivity:

8,114,833*PED

NDA:

022341

Dosage:

SOLUTION;SUBCUTANEOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for victoza

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Chicago	Early Phase 1
Carmot Therapeutics, Inc.	Phase 1
Yale University	Phase 3

See all victoza clinical trials

Pharmacology for victoza

Drug Class	GLP-1 Receptor Agonist
Mechanism of Action	Glucagon-like Peptide-1 (GLP-1) Agonists

Paragraph IV (Patent) Challenges for VICTOZA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VICTOZA	Injection	liraglutide	18 mg/3 mL prefilled syringe	022341	1	2016-12-12

US Patents and Regulatory Information for victoza

victoza is protected by two US patents.

This potential generic entry date is based on patent 8,114,833.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	8,114,833*PED				Y
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	AP1	RX	Yes	Yes	9,968,659*PED				Y

Expired US Patents for victoza

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	RE41956*PED
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,004,297
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	RE43834
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	7,235,627
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,458,924
Novo Nordisk Inc	VICTOZA	liraglutide	SOLUTION;SUBCUTANEOUS	022341-001	Jan 25, 2010	6,235,004

International Patents for victoza

See the table below for patents covering victoza around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	148609	DOSE SETTING LIMITER
Denmark	1250167
World Intellectual Property Organization (WIPO)	2004004812
Poland	2109474
European Patent Office	3423082	LIRAGLUTIDE UTILISÉ DANS LE TRAITEMENT DE MALADIES CARDIOVASCULAIRES (LIRAGLUTIDE IN CARDIOVASCULAR CONDITIONS)
European Patent Office	1056774

Supplementary Protection Certificates for victoza

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2597103	2017/015	Ireland		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912
0944648	SPC/GB09/058	United Kingdom		PRODUCT NAME: LIRAGLUTIDE; REGISTERED: UK EU/1/09/529/001 20090630
0944648	09C0054	France		PRODUCT NAME: LIRAGLUTIDE; REGISTRATION NO/DATE IN FRANCE: EU/1/09/529/001 DU 20090630; REGISTRATION NO/DATE AT EEC: EU/1/09/529/001 DU 20090630
2209800	SPC/GB14/079	United Kingdom		PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF, AND LIRAGLUTIDE, OR PHARMACEUTICALLY ACCEPTABLE SOLVATES, HYDRATES, OR SALTS THEREOF; REGISTERED: CH 65041 20140912; UK EU/1/14/947 20140922
2209800	132014902311502	Italy		PRODUCT NAME: INSULINA DEGLUDEC/LIRAGLUTIDE(XULTOPHY); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/947, 20140918
2209800	122014000114	Germany		PRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918

Market Dynamics and Financial Trajectory for VICTOZA

Last updated: December 16, 2025

Executive Summary

VICTOZA, a branded pharmacological agent developed by Novo Nordisk, primarily treats type 2 diabetes mellitus (T2DM) and obesity-related indications. As a glucagon-like peptide-1 (GLP-1) receptor agonist, VICTOZA's market presence has expanded amid rising global diabetes prevalence, increasing obesity rates, and evolving regulatory landscapes. This report analyzes current market dynamics, competitive positioning, regulatory influences, revenue forecasts, and strategic outlooks, offering vital insights for stakeholders and investors.

---

What Is VICTOZA and How Does It Function in the Market?

Attribute	Details
Generic Name	Liraglutide
Brand Name	VICTOZA
Manufacturer	Novo Nordisk A/S
FDA Approval Date	January 2010 for diabetes; 2021 for obesity (Wegovy) indications
Drug Class	GLP-1 receptor agonist, injectable
Indications	T2DM management, obesity (market extension)
Formulation	Subcutaneous injection, pre-filled pen

Market Role Summary:
VICTOZA revolutionized T2DM management, offering effective glycemic control with added cardiovascular benefits. Its extension into obesity treatment via higher-dose formulations (e.g., Wegovy) has broadened revenue sources.

---

Key Market Drivers for VICTOZA

Driver Category	Details	Impact
Rising Diabetes Prevalence	Globally, 537 million adults affected (2021 estimate)	Expands potential user base significantly
Obesity Epidemic	Over 1.9 billion adults overweight; 650 million obese (WHO, 2022)	Drives demand for weight management therapies like Wegovy
Cardiovascular Disease (CVD) Benefits	Proven to reduce major adverse cardiovascular events (REWIND trial)	Enhances clinical value proposition
Preference for Injectable Therapies	Increased adoption due to efficacy and safety profiles	Sustains demand in specialty markets
Regulatory Approvals	Expanded indications boost market access	Facilitates market penetration

---

Competitive Landscape and Market Share

Major Competitors:

Brand	Active Ingredient	Indications	Market Position (2023)	Key Traits
Ozempic	Semaglutide	T2DM, weight loss	Leader in GLP-1 class	Once weekly, superior efficacy
Mounjaro	Tirzepatide	T2DM, obesity	Emerging competitor	Dual mechanism (GIP + GLP-1)
Saxenda	Liraglutide (lower dose)	Obesity	Niche in weight management	Similar molecule, lower dose

Market Share Breakdown (2023):

Product	Estimated Market Share	Notes
Ozempic	~45%	Dominates GLP-1 segment; high prescriber acceptance
VICTOZA	~25-30%	Significant legacy; expanding into obesity
Wegovy	~15%	Rapid growth, new entrant
Others	~10-15%	Mounjaro, Saxenda, generics

---

Regulatory and Policy Influences

FDA and EMA Approvals

Year	Event	Impact
2010	FDA approval of VICTOZA for T2DM	Market entry and establishment
2021	Approval of Wegovy (higher-dose liraglutide) for obesity	Market extension, increased revenues

Regulatory policies increasingly favor GLP-1 therapies owing to their cardiovascular and metabolic benefits, prompting accelerated approvals in multiple jurisdictions.

Pricing and Reimbursement Trends

Policy Element	Trend	Effect on VICTOZA	Source
Reimbursement Expansion	Increasingly favorable	Higher accessibility	[2]
Price Competition	Rising pressure	Margin compression	[3]

The high cost of injectable GLP-1 drugs challenges profitability but is offset by premium pricing positioning and robust clinical benefits.

---

Financial Trajectory: Revenue, Costs, and Growth Prospects

Historical Revenue Performance (2020-2022)

Year	Revenue (USD Billion)	Growth Rate	Notes
2020	$2.1	—	Base year amid pandemic disruptions
2021	$3.1	+47.6%	Driven by obesity indications and entering Q4
2022	$4.1	+32.3%	Substantial expansion in obesity segment and new markets

Projection Scenario Analysis (2023-2027)

Scenario	Assumptions	Estimated CAGR	Key Drivers
Optimistic	Rapid adoption of Wegovy, emerging markets, further clinical approvals	16-20%	Expanded indications, higher dosing options
Moderate	Steady growth with market maturation and competition	8-12%	Regulatory delays, payer pressures
Pessimistic	Market saturation, pricing constraints, adverse policies	<8%	Patent challenges, biosimilar entry

Forecasts indicate VICTOZA’s revenues could range between $4.5 billion to over $6 billion by 2027 under optimistic assumptions, with continued growth mainly driven by obesity treatment sales and cardiovascular indications.

Cost Structure & Margin Outlook

Element	% of Revenue	Trend	Implication
R&D	~15-18%	Steady	Investment in next-gen therapies
Manufacturing	~20%	Declining with scale	Improved margins
Marketing	~10-12%	Increased for new indications	Boosts brand awareness

Gross margins are projected to stabilize around 70-75%, with net margins improving as market share increases.

---

Strategic Considerations and Future Outlook

Portfolio Expansion and Pipeline

• Next-Generation GLP-1s: Novo Nordisk developing oral formulations and dual agonists.
• Combination Therapies: Potential for dual-action injections for enhanced efficacy.
• Global Market Penetration: Focus on emerging markets with high diabetes prevalence.

Market Challenges

• Patent Expirations: Potential biosimilar entries post-2028 could impact pricing and market share.
• Pricing Pressures: Payers demanding discounts, especially in markets with cost-sensitive healthcare systems.
• Competitive Innovation: Semaglutide-based products (Ozempic, Wegovy) outperform in efficacy, threatening VICTOZA’s dominance.

Growth Opportunities

Opportunity Area	Strategic Actions	Expected Outcomes
Obesity Treatment	Accelerate approval and access globally	Enter new lucrative markets
Cardiovascular Indications	Invest in robust clinical trials	Increase prescriber confidence
Digital Health Integration	Connect with diabetes management platforms	Improve adherence, clinical outcomes

---

Key Takeaways

• Market Expansion: VICTOZA's revenue growth is buoyed by its strong position in T2DM management and emerging obesity markets, with projections favoring sustained expansion.
• Competitive Edge: While Ozempic leads in efficacy, VICTOZA retains market share through established clinical data and early market entry.
• Regulatory Trends: Increasing approval for obesity and cardiovascular indications positions VICTOZA favorably; however, potential biosimilar threats loom post-patent expiry.
• Financial Outlook: With an estimated CAGR of around 10-15% through 2027, VICTOZA's revenue could surpass $6 billion, driven by demographic shifts and expanded indications.
• Strategic Focus: Continued innovation, pipeline development, and global market penetration are essential to maintaining competitive advantage.

---

FAQs

Q1: How does VICTOZA compare to its main competitor, Ozempic, in efficacy?
Ozempic (semaglutide) has demonstrated superior glycemic control and weight loss efficacy in clinical trials, contributing to its dominant market position. However, VICTOZA remains competitive due to its proven cardiovascular benefits and longer market presence.

Q2: What are the main regulatory hurdles VICTOZA faces?
While approvals have been broadening, future hurdles include biosimilar entry after patent expiry, potential restrictions based on cost-effectiveness evaluations, and varying regulatory acceptance in emerging markets.

Q3: How significant is the obesity segment for VICTOZA’s future revenues?
Extending into obesity treatment with higher-dose formulations like Wegovy represents a substantial growth driver, potentially adding billions in revenue globally due to rising obesity rates.

Q4: What impact do patent expirations have on VICTOZA’s profitability?
Patent expiry, expected around 2028, risks biosimilar competition, which can compress prices and market share. Strategic patent extensions and pipeline diversification are crucial mitigators.

Q5: Is VICTOZA adaptable for use in combination therapies?
Yes. Novo Nordisk is exploring fixed-dose combinations of GLP-1 with other agents to enhance therapeutic outcomes, which could reinforce VICTOZA’s market position.

---

References

[1] International Diabetes Federation. (2022). “IDF Diabetes Atlas”, 10th Edition.
[2] IQVIA. (2023). “Global Use of Medicines and Pricing Trends.”
[3] Novo Nordisk Annual Reports. (2020-2022).
[4] WHO. (2022). “Obesity and Overweight Data.”
[5] ClinicalTrials.gov. (2023). “Active Trials on GLP-1 Receptor Agonists.”

---

In conclusion, VICTOZA’s market trajectory remains promising, driven by demographic shifts, expanding indications, and clinical efficacy. Strategic positioning, innovation, and navigating regulatory landscapes will be key to maximizing its financial potential over the coming years.